ArticleESMO open2026
Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesenchymal chondrosarcoma (MCS) is an ultra-rare sarcoma, molecularly defined by the HEY1::NCOA2 fusion, and characterized by a poor prognosis in the advanced phase. Data on the activity of systemic agents in MCS are only retrospective and limited to case reports or heterogeneous series. We report the results of an Italian, multicentric, retrospective study on the activity of cytotoxic chemotherapy in patients with MCS. PATIENTS AND
methodsThis retrospective, multicentre Italian Sarcoma Group study included patients with molecularly confirmed MCS, treated with anthracycline-based chemotherapy, high-dose ifosfamide (HD-IFX), or trabectedin between 2000 and 2022. Response to treatment was assessed retrospectively through imaging review. Survival outcomes were estimated by the Kaplan-Meier method.
resultsThirty-five patients were identified (19 = localized disease, 16 = advanced disease). Anthracycline-based regimens yielded an overall response rate (ORR) of 26% [95% confidence interval (CI) 15% to 50%]. Among patients with localized disease, Ewing-like regimens showed an ORR of 33.3% (95% CI 9.9% to 65.1%), median relapse-free survival (mRFS) of 86.9 months, and 5-year overall survival of 95%; other anthracycline combinations had an ORR of 40% (95% CI 5.3% to 85.3%) and mRFS of 32.6 months. In advanced disease, Ewing-like regimens yielded an ORR of 16.7% (95% CI 0.4% to 64.1%) and median progression-free survival (mPFS) of 13.2 months, while other anthracycline regimens resulted in an ORR of 22.2% (95% CI 15% to 50%) and mPFS of 9.3 months. HD-IFX showed no responses, with early progression in all cases. Trabectedin achieved stable disease in all four treated patients, with a median PFS of 16.9 months.
conclusionsThis multicentre study confirms that anthracycline-based regimens show activity in MCS, with responses more in line with soft tissue sarcoma than Ewing sarcoma. Their benefit in localized disease remains uncertain, but (neo)adjuvant chemotherapy with Ewing-like regimens should be considered for patients eligible for surgery. In advanced disease, trabectedin may provide prolonged disease control after anthracyclines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.